EMJ Dermatology 6 [Suppl 3] . 2019

In this issue

Prof Bieber opened the symposium by explaining that there has been a revolution in the management of patients with moderate-to-severe atopic dermatitis (AD) since the approval of the first biologic, dupilumab, in 2017.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.